JAZZ
JAZZ PHARMACEUTICALS PLC
JAZZ PHARMACEUTICALS PLC historical holders
total: 5
Muhlenkamp & Co JAZZ PHARMACEUTICALS PLC transactions over time
- Total transactions:
- 10
- New positions:
- 1
- Sold out:
- 1
- Added:
- 5
- Reduced:
- 3
- Held since:
- 2018 Q2
- Held for:
- 9 quarters
- Latest activity:
- 2021 Q1
Ronald Muhlenkamp has been an institutional investor in JAZZ PHARMACEUTICALS PLC (JAZZ) since 2018 Q2. According to 2026 Q1 report, Ronald Muhlenkamp doesn't hold any shares. The fund/company first acquired JAZZ in 2018 Q2, initially purchasing 37,155 shares. Since the initial investment, Muhlenkamp & Co has made 9 more transactions in this position.
When did Ronald Muhlenkamp exit their JAZZ position?
Ronald Muhlenkamp no longer holds JAZZ PHARMACEUTICALS PLC (JAZZ). They sold off their entire position in 2021 Q1, closing out an investment that began in 2018 Q2.
When did Ronald Muhlenkamp first invest in JAZZ?
Ronald Muhlenkamp first invested in JAZZ PHARMACEUTICALS PLC (JAZZ) in 2018 Q2 at the reported quarter-end price of $172.31 per share, acquiring 37,155 shares in their initial purchase.
What is Ronald Muhlenkamp's average cost basis for JAZZ?
Based on historical transaction data, Ronald Muhlenkamp's estimated cost basis for JAZZ PHARMACEUTICALS PLC (JAZZ) is approximately $165.80 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $165.80
- Weighted AVG sell price:
- $164.72
JAZZ transactions history by Muhlenkamp & Co
10 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2021 Q1
|
0.00%
|
0
|
$165.04
|
|
-100% (-50,460)
|
-3.35%
|
|
2020 Q4
|
3.35%
|
$165.04
|
+0.42% (+213)
|
|||
|
2020 Q3
|
3.71%
|
$142.60
|
+0.97% (+484)
|
|||
|
2020 Q2
|
2.94%
|
$110.34
|
+0.28% (+137)
|
|||
|
2019 Q4
|
3.24%
|
$149.28
|
+36.93% (+13,384)
|
|||
|
2019 Q3
|
2.26%
|
$128.14
|
+0.11% (+39)
|
|||
|
2019 Q2
|
2.51%
|
$142.56
|
-0.33% (-121)
|
|||
|
2019 Q1
|
2.46%
|
$142.96
|
-1.75% (-647)
|
|||
|
2018 Q3
|
2.67%
|
$168.13
|
-0.50% (-184)
|
|||
|
2018 Q2
|
2.46%
|
$172.31
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.